Tuesday October 17, 2017 0 comments
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it has entered into a securities purchase agreement with investors for the registered sale of approximately $6.75 million of shares of common stock at a purchase price of $0.875 per share.
Closing of the sale of shares is expected to take place on or about Oct. 18, 2017, subject to certain customary closing conditions.
Ampio said it intends to use net proceeds from the offering for working capital and general corporate purposes, including funding of the Ampion™ clinical trial.
Joseph Gunnar & Co., LLC, and Fordham Financial Management, Inc. are acting as placement agents for the offering.
The sale of the common stock is being offered by the company pursuant to a shelf registration statement on Form S-3 (Registration No. 333-217094), which was declared effective by the Securities and Exchange Commission (the "SEC") on April 20, 2017.
A final prospectus supplement will be filed with the SEC and will form a part of the effective registration statement.
Copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained, when available, by contacting Joseph Gunnar & Co., LLC, Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, telephone 212-440-9600, email: [email protected] or Fordham Financial Management, Inc. at: 17 Battery Place, Suite 643, New York, NY 10004, by telephone at 212-732-8500, or by email at [email protected]